Cancer Clinical Trial - MedImmune D419NC00001

CONDITIONS(S): Colorectal - TRIAL: MedImmune D419NC00001 - A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of Durvalumab (MEDI4736) in combination with monalizumab (IPH2201) in Adult Subjects with selected advanced solid tumors and the combination of durvalumab and monalizumab (IPH2201) standard of care systemic therapy with or without biological agent and monalizumab (IPH2201) with biological agent administered to subjects with recurrent or metastatic colorectal cancer (CRC).

Drug

Combination Product: Intervention

Trial Type

Interventional

Age Range

18 years or older

Condition

Colorectal cancer Advanced solid tumors

Keywords

MedImmune | Colorectal cancer | Durvalumab